Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76278 | 1.00 | F10 (0.66) | F10NPC1RAB9ATDP1MAPT | |
| SCHEMBL77603 | 0.91 | F10 (0.77) | F10MAPT | |
| SCHEMBL77604 | 0.91 | F10 (0.77) | F10MAPT | |
| SCHEMBL76651 | 0.89 | F10 (0.57) | F10NPC1RAB9ATDP1 | |
| SCHEMBL76650 | 0.89 | F10 (0.57) | F10NPC1RAB9ATDP1 | |
| SCHEMBL76830 | 0.89 | F10 (0.51) | F10NPC1RAB9ATDP1MMP2 | |
| SCHEMBL76829 | 0.89 | F10 (0.51) | F10NPC1RAB9ATDP1MMP2 | |
| SCHEMBL2640138 | 0.88 | F10 (0.51) | F10NPC1RAB9ATDP1 | |
| SCHEMBL78053 | 0.87 | F10 (0.69) | F10NPC1RAB9ATDP1 | |
| SCHEMBL78052 | 0.87 | F10 (0.69) | F10NPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | claimed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | claimed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | claimed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | F10 5/4885NPC1 2731/4885RAB9A 1813/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | F10 22/4885NPC1 1383/4885RAB9A 3292/4885 |
| US-20060183739-A1 | Carbonyl compounds | F2, F11, PDHX | F10 5/4885NPC1 2731/4885RAB9A 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.